Steve Bryson, PhD,  science writer—

One year of rituximab therapy was effective in people with myasthenia gravis (MG) ages 65 or older, with no significant differences in response or safety seen in this older patient group relative to younger patients, an analysis of medical records found. “Rituximab should be considered in the treatment…

Altered production of circular RNA impaired the process of muscle cell growth and regeneration in people with myasthenia gravis (MG), a study has suggested. More studies investigating the role of circular RNA in MG may identify new molecular markers to monitor disease progression and reveal therapeutic targets, the researchers…

Treatment with immunosuppressant medications can delay disease progression in patients with ocular myasthenia gravis, which affects only eye muscles, to a more generalized form in which other muscles are affected, a study has found. The findings also showed that thymus gland abnormalities, as well as irregular results on facial…

Editor’s note: The Myasthenia Gravis News team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. People with myasthenia gravis (MG) have used a patient-led analysis to document and share with healthcare professionals their…

Editor’s note: The Myasthenia Gravis News team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference Soliris (eculizumab), a treatment for people with generalized myasthenia gravis…

Myasthenia gravis (MG) tends to be more severe and generalized at diagnosis, and myasthenic crises more frequent in patients whose disease is associated with thymoma, an analysis of a patient registry has found. MG patients with thymoma also required more immunosuppressive and immunomodulatory therapies,…

People with myasthenia gravis (MG), particularly those with late-onset and thymoma-associated MG — disease linked to a tumor in the thymus gland — have a higher risk of developing other types of cancer, according to an analysis of a Swedish national registry. The results also…

People with refractory generalized myasthenia gravis (gMG) who responded to Soliris (eculizumab) were able to reduce the use of immunosuppressive therapies, data from an extension study of the Phase 3 REGAIN trial showed. Tapering off immunosuppressants…

An analysis of the thymuses removed from people with myasthenia gravis (MG) found lower levels of micro RNA molecules (miRNAs) that may contribute to disease development by favoring increased production of pro-inflammatory proteins and cells, a study suggests. …

A Japanese man with generalized myasthenia gravis (gMG) experienced a severe worsening of symptoms after discontinuing treatment with Soliris (eculizumab), a case study reported.  Titled “Severe worsening of myasthenic symptoms after…